van der Marel Sander, Majowicz Anna, van Deventer Sander, Petry Harald, Hommes Daniel W, Ferreira Valerie
Department of Research and Development, Amsterdam Molecular Therapeutics BV, 1105 BA Amsterdam, The Netherlands.
World J Gastrointest Pathophysiol. 2011 Dec 15;2(6):114-22. doi: 10.4291/wjgp.v2.i6.114.
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory disorders most commonly affecting young adults. Currently available therapies can result in induction and maintenance of remission, but are not curative and have sometimes important side effects. Advances in basic research in IBD have provided new therapeutic opportunities to target the inflammatory process involved. Gene and cell therapy approaches are suitable to prevent inflammation in the gastrointestinal tract and show therefore potential in the treatment of IBD. In this review, we present the current progress in the field of both gene and cell therapy and future prospects in the context of IBD. Regarding gene therapy, we focus on viral vectors and their applications in preclinical models. The focus for cell therapy is on regulatory T lymphocytes and mesenchymal stromal cells, their potential for the treatment of IBD and the progress made in both preclinical models and clinical trials.
炎症性肠病(IBD)是一组最常影响年轻人的慢性炎症性疾病。目前可用的疗法可诱导并维持缓解,但无法治愈,且有时会产生严重的副作用。IBD基础研究的进展为针对相关炎症过程提供了新的治疗机会。基因和细胞疗法适用于预防胃肠道炎症,因此在IBD治疗中显示出潜力。在本综述中,我们介绍了基因和细胞疗法领域的当前进展以及IBD背景下的未来前景。关于基因疗法,我们重点关注病毒载体及其在临床前模型中的应用。细胞疗法的重点是调节性T淋巴细胞和间充质基质细胞、它们在IBD治疗中的潜力以及在临床前模型和临床试验中取得的进展。